Vortioxetine (tablet)

DRUG2 trials

Sponsors

H. Lundbeck A/S, Marianna Amboni

Conditions

Depression Not Otherwise SpecifiedDepressive Disorder, MajorFreezing of GaitParkinson Disease, Idiopathic

Phase 2

Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder

CompletedNCT02919501

H. Lundbeck A/SDepressive Disorder, Major

Start: 2016-09-27End: 2017-04-27Updated: 2018-06-20

Phase 4

Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease

Not yet recruitingNCT06805266

Marianna AmboniDepression Not Otherwise Specified, Freezing of Gait, Parkinson Disease, Idiopathic

Start: 2025-02-28End: 2027-02-28Target: 40Updated: 2025-02-06

Related Papers

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder

International Clinical Psychopharmacology2019-05-1616 citations